CheckMate 901 trial
Presented by Prof Emmanuel Seront (Clinique Universitaires Saint-Luc, Brussels, Belgium)
Prof Emmanuel Seront, a medical oncologist at Clinique Universitaires Saint-Luc in Brussels, shares his insights on a post hoc analysis of the CheckMate 901 trial.
The CheckMate 901 trial is a large phase III study that evaluated the efficacy of combining nivolumab (NIVO) with gemcitabine-cisplatin (GC) in first-line treatment for mUC. Lymph node (LN)-only metastatic disease is considered a favourable prognostic factor in mUC patients, with a subset achieving durable disease-free and treatment-free survival following GC, with or without surgical consolidation. An exploratory characterization of patients with CR identified a group enriched with LN-only disease.
In patients with LN-only mUC, the combination of NIVO and GC induced durable disease control and provided clinically meaningful improvements in OS and PFS compared to GC alone. Pelvic lymph nodes were associated with the highest complete response rate compared to chemotherapy alone.
This regimen shows promise in patients with LN-only mUC, provided the patient is eligible for cisplatin.
References:
Galsky MD, ASCO24 #4509
